J&J Wins Rapid Approval Of Specialized TB Drug

Law360, New York (January 2, 2013, 5:47 PM EST) -- The U.S. Food and Drug Administration on Monday announced it has granted early approval to Johnson & Johnson's Sirturo as the first medication for a rare and stubborn form of tuberculosis, saying the need for effective treatment outweighed lingering concerns about potentially deadly side effects.

Sirturo, or bedaquiline, is being developed by J&J unit Janssen Therapeutics and targets more than 600,000 patients around the world suffering from multidrug-resistant tuberculosis, a tough-to-fight strain of the bacterial lung infection that overall infects about 12 million people globally. Prevalence is...
To view the full article, register now.